Dr Johnson on the Efficacy of RMC-6236 in KRAS-Mutant NSCLC
November 28th 2023Melissa L. Johnson, MD, discusses the preliminary efficacy findings from the phase 1 RMC-6236-001 trial in patients with non–small cell lung cancer harboring KRAS mutations and details the significance of these findings for patients within the KRAS G12X-mutant NSCLC population.
Read More
Dr Johnson on the Initial Efficacy of Ifinatamab Deruxtecan in Refractory SCLC
September 18th 2023Melissa L. Johnson, MD, discusses findings from a subgroup analysis of outcomes with ifinatamab deruxtecan in patients with refractory small cell lung cancer, which she presented at the 2023 IASLC World Conference on Lung Cancer.
Read More
Dr Johnson on BL-B01D1 in Locally Advanced or Metastatic Solid Tumors
June 8th 2023Melissa L. Johnson, MD, discusses findings from the phase 1 BL-B01D1-101 trial investigating the efficacy and safety of the EGFR- and HER3-directed antibody-drug conjugate BL-B01D1 in patients with locally advanced or metastatic solid tumors, including non–small cell lung cancer.
Read More